New drug trial offers hope for Tough-to-Treat breast cancer
NCT ID NCT07299825
Summary
This study is testing an experimental drug called A166 for people with advanced HER2-positive breast cancer that has spread and has stopped responding to certain other powerful treatments. About 40 participants will receive A166 through an IV every three weeks to see if it can shrink tumors and control the cancer. The main goal is to measure how many patients see their tumors get significantly smaller.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER-2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Provincial Cancer Hospital
RECRUITINGZhenzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.